NCT05582590 - Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

August 25, 2027

Conditions

Oropharyngeal CancerHuman Papilloma VirusHead and Neck CancerHead and Neck Squamous Cell CarcinomaOropharyngeal Squamous Cell CarcinomaOropharyngeal Cancer, MetastaticHead and Neck Cancer MetastaticHPV-Related Squamous Cell CarcinomaHPV-Related Mucosal Head and Neck Squamous Cell CarcinomaRelapsed Oropharyngeal SCCRefractory Oropharyngeal Squamous Cell Carcinoma

Interventions

DRUG

Fludarabine

Lymphodepletion Chemotherapy on Days -5, -4, and -3 before Cycle 1 ONLY

DRUG

Cyclophosphamide

Lymphodepletion Chemotherapy administered on Days -5, -4, and -3 before Cycle 1 ONLY

BIOLOGICAL

NEXI-003 T cells

Adoptive Cell Therapy specified dose on specified day(s)